Company / Shareholders' Equity
Harmony Biosciences Holdings, Inc. Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$870.2M
FY2025
5-year range
-$422.9M / $870.2M
FY2021-FY2025
Trend
+32.0%
vs FY2024
Sector context
#54 of 213
Health Care
What the data says
Harmony Biosciences Holdings, Inc.'s shareholders' equity of $870M is higher than 75% of companies in the Health Care sector (FY2025). Shareholders' Equity has increased for 4 consecutive years, from -$423M in FY2021 to $870M in FY2025.
Based on SEC 10-K filings.
$870M in FY2025 with a 3-year CAGR of +29.3%. Top quartile in the Health Care sector.
Improved from $467M to $870M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +29.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-65.9% below sector average
Key checks
Key Insights
- Harmony Biosciences Holdings, Inc.'s shareholders' equity has grown for 4 consecutive years.
- 3-year CAGR of +29.3%, indicating consistent growth.
- In FY2025, shareholders' equity increased 32.0% year-over-year.
- Ranks #54 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $870.2M | +32.0% |
| FY2024 | $659.2M | +41.1% |
| FY2023 | $467.0M | +15.9% |
| FY2022 | $402.8M | +195.3% |
| FY2021 | -$422.9M | -74.3% |
| FY2020 | -$242.7M | +42.6% |
| FY2019 | -$422.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026